Node K

References (3)

Title : A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction - Kitsuka_2022_Sci.Rep_12_6923
Author(s) : Kitsuka T , Shiraki A , Oyama JI , Nakagami H , Tanaka A , Node K
Ref : Sci Rep , 12 :6923 , 2022
Abstract : Kitsuka_2022_Sci.Rep_12_6923
ESTHER : Kitsuka_2022_Sci.Rep_12_6923
PubMedSearch : Kitsuka_2022_Sci.Rep_12_6923
PubMedID: 35484372

Title : Treatment with anagliptin, a DPP-4 inhibitor, decreases FABP4 concentration in patients with type 2 diabetes mellitus at a high risk for cardiovascular disease who are receiving statin therapy - Furuhashi_2020_Cardiovasc.Diabetol_19_89
Author(s) : Furuhashi M , Sakuma I , Morimoto T , Higashiura Y , Sakai A , Matsumoto M , Sakuma M , Shimabukuro M , Nomiyama T , Arasaki O , Node K , Ueda S
Ref : Cardiovasc Diabetol , 19 :89 , 2020
Abstract : Furuhashi_2020_Cardiovasc.Diabetol_19_89
ESTHER : Furuhashi_2020_Cardiovasc.Diabetol_19_89
PubMedSearch : Furuhashi_2020_Cardiovasc.Diabetol_19_89
PubMedID: 32539832

Title : Effect of Anagliptin and Sitagliptin on Low-Density Lipoprotein Cholesterol in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: Rationale and Study Design of the REASON Trial - Ueda_2018_Cardiovasc.Drugs.Ther_32_73
Author(s) : Ueda S , Shimabukuro M , Arasaki O , Node K , Nomiyama T , Morimoto T
Ref : Cardiovasc Drugs Ther , 32 :73 , 2018
Abstract : Ueda_2018_Cardiovasc.Drugs.Ther_32_73
ESTHER : Ueda_2018_Cardiovasc.Drugs.Ther_32_73
PubMedSearch : Ueda_2018_Cardiovasc.Drugs.Ther_32_73
PubMedID: 29435776